KRAS and lung carcinoma: A vaccine using peptides computationally predicted to target neoantigens derived from mutant KRAS elicited an immune response in a mouse model of KRAS-driven lung cancer in which mice were vaccinated prior to activating the mutant KRAS gene [131].